New Novo drug delivers significant weight-loss benefits in diabetes trial
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline
Related reading
New Novo Nordisk drug could beat market leaders for weight loss, early results…
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Novo Nordisk weight-loss drug wins US approval as a daily pill
Shares in Danish company rise as drugmaker secures lead in oral obesity treatment
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Eli Lilly wins US approval for weight-loss drug in pill form
New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs